EMEA-001796-PIP03-16-M02
Key facts
Invented name |
Calquence
|
Active substance |
Acalabrutinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0408/2021
|
PIP number |
EMEA-001796-PIP03-16-M02
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
ACERTA PHARMA, BV
Tel. +31 412700 576 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|